Complete the statement about a new carbamazepine prescription for a client taking apixaban for atrial fibrillation.
Drop-down Cloze
Choose your responses, then check the answer.
Explanation
Carbamazepine is a combined P-gp and strong CYP3A4 inducer that can decrease apixaban exposure and increase thromboembolic risk; the combination should be avoided and an alternative plan obtained.
Quick answer The prescription creates an enzyme-induction loss of anticoagulant protection.
Why this is correct Apixaban labeling says to avoid combined P-gp and strong CYP3A4 inducers such as carbamazepine because exposure decreases and stroke or systemic embolism risk can rise.
Easy analogy or mental picture Carbamazepine opens faster exit routes, so apixaban leaves before it can provide the intended protection.
Memory hook Strong inducer means apixaban lower, stroke risk higher.
NCLEX decision rule Clarify the combination before administration rather than compensating with an unapproved self-selected dose.
Why the other choices are wrong Increasing apixaban without authorization or relying on routine INR testing does not solve this interaction.
References
1FDA: ELIQUIS Prescribing InformationAvoid combined P-gp and strong CYP3A4 inducers because apixaban exposure decreases and thromboembolic risk rises
Induction interaction checkVerify seizure indication, interacting alternatives, apixaban indication and dose, adherence, renal and hepatic function, and the authorized replacement strategy.